Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial. - Wikidata - awgldk - TriplyDB

Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial.

Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial.

http://www.wikidata.org/entity/Q53124033

about

Aflibercept Molecular targeted therapy to improve radiotherapeutic outcomes for non-small cell lung carcinoma The Evolution of Therapies in Non-Small Cell Lung Cancer Efficacy of Addition of Antiangiogenic Agents to Taxanes-Containing Chemotherapy in Advanced Nonsmall-Cell Lung Cancer: A Meta-Analysis and Systemic Review Molecular targets in urothelial cancer: detection, treatment, and animal models of bladder cancer Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.Ziv-aflibercept use in metastatic colorectal cancer.Targeted inhibition of VEGF receptor 2: an update on ramucirumab.Pulmonary adenocarcinoma: implications of the recent advances in molecular biology, treatment and the IASLC/ATS/ERS classification.Incidence and risk of proteinuria with aflibercept in cancer patients: a meta-analysis.The efficacy of combining antiangiogenic agents with chemotherapy for patients with advanced non-small cell lung cancer who failed first-line chemotherapy: a systematic review and meta-analysis Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose.Combination of Iodine-125 brachytherapy and chemotherapy for locally recurrent stage III non-small cell lung cancer after concurrent chemoradiotherapy The role of docetaxel in the treatment of non-small cell lung cancer lung cancer: an update.Incidence and risk of severe infections associated with aflibercept in cancer patients: a systematic review and meta-analysis Patient preference and decision-making for initiating metastatic colorectal cancer medical treatment.Targeted therapies in non-small cell lung carcinoma: what have we achieved so far?Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues.Risk of venous and arterial thromboembolic events associated with anti-VEGF agents in advanced non-small-cell lung cancer: a meta-analysis and systematic review.Emerging options for the management of non-small cell lung cancer.Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer.Targeted therapy for non-small-cell lung cancer: past, present and future.Aflibercept in lung cancer.Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer Understanding and targeting resistance to anti-angiogenic therapies.Antiangiogenic agents and chemotherapy in advanced non-small cell lung cancer: a clinical perspective.The continuing role of chemotherapy for advanced non-small cell lung cancer in the targeted therapy era.Aflibercept--a decoy VEGF receptor.Risk of hypertension in cancer patients treated with aflibercept: a systematic review and meta-analysis.Risk of gastrointestinal perforation in cancer patients treated with aflibercept: a systematic review and meta-analysis.Recognizing and managing left ventricular dysfunction associated with therapeutic inhibition of the vascular endothelial growth factor signaling pathway.Nintedanib for the treatment of patients with advanced non-small-cell lung cancer.The role of anti-angiogenesis in non-small-cell lung cancer: an update.An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer.Bevacizumab in advanced lung cancer: state of the art.Anti-angiogenesis in Personalized Therapy of Lung Cancer.Anti-EGFR and antiangiogenic monoclonal antibodies in metastatic non-small-cell lung cancer.Second-Line Treatment of Non-Small Cell Lung Cancer: New Developments for Tumours Not Harbouring Targetable Oncogenic Driver Mutations.

P2860

Q24600199-D55C1C1F-B496-48C4-BA66-59A4ED3CC257 Q26767182-235BA55D-2493-4903-9F83-5A736CC74855 Q26786932-75914360-39F0-4D65-B253-FC0D6B9B171F Q26801118-9D80D187-54EB-4839-8F59-FA3671CF1DED Q28076041-29EFC17D-B346-4899-9C51-5BBE770D07A4 Q30356434-AA9F90A9-324F-45D3-8A7E-899C7A69BD13 Q33418555-5D0F4A2B-6B3A-47A4-A44D-0995AA2FC199 Q33886059-71FC971D-1BC8-474B-8CBE-FE8CD42B943F Q34040956-57C262A9-8B63-4D9F-9CBE-68404BA9F2FF Q34404209-B67E9E2B-02FD-4B4B-BCEB-F9B5EC3AE034 Q34445829-1377E4F3-9F64-40C4-907A-B84E322F9DAF Q35649624-4B246DBC-4F60-40E5-A75E-7B57234AE3FF Q35674153-8E0B5044-F17C-463C-BDAE-34AFF7E37CD6 Q36131115-C157D999-70E7-4D1E-AFAD-633A676C7E74 Q36142491-920A03EA-4A62-4110-BE08-4C2CE30AE0E1 Q36410268-06A21F8D-6F79-494A-A872-1CEDB766671A Q36578276-2DE1DC03-E6CD-48FF-BC8E-DDB178DBB118 Q36999705-2AF89483-19B8-4EC0-9CD3-8D022DB387C1 Q37031917-FD6D74A5-6370-4951-96C8-C6D3995E7D8D Q37042424-5F2B6153-A6B8-4FDC-BF96-BDA7EAD43C51 Q37269316-B633FA9C-C515-4BEE-A657-0D224C825021 Q37347532-974990FF-2BC9-48BB-8A89-88C8630E2886 Q37558971-B22CC5A8-BAE4-4DAC-B9C0-32ACC8826618 Q37709922-AA56DBF0-C333-4D8F-A559-456355667227 Q38063939-4E19FD23-68CC-40F8-8137-395C78206555 Q38125964-92CB05E0-F23A-4978-8A5C-425FAE0C08A0 Q38133568-19CCE8E3-E221-4811-A092-7F399DB4DF78 Q38153445-79BC2BBB-FC35-43A8-B767-ED40884225E9 Q38155855-2B9C85E8-1EAF-4E01-811A-6836D6A34E29 Q38180313-F8F8FFBD-948F-46A4-B193-3A6CF327A392 Q38184936-0B48427D-F1BE-4E3C-83C2-32F7C5EB722E Q38234800-77302C11-391F-4012-84C4-88CD0958A095 Q38237495-518FDDE4-761D-42B2-ACC4-B173A21E449C Q38239545-BC718E84-FC76-4874-AC76-6A9B486C7A8A Q38462638-F80623E1-C091-42DF-8E43-9E5F0E7838AB Q38525073-FA495315-3056-4A1A-B880-BA49D1CDF0BD Q38641871-3EF3CFCA-5D53-4B62-825C-22D258EE96D7 Q38669276-5AA8729C-10A5-4E04-B59A-C34E544A777B Q38763641-AFC941D7-6AE1-4E34-91DA-3251A6CBE408 Q38936376-613F05E1-8F2A-4D8A-8294-FC117AD7422B

P2860

Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial.

http://www.wikidata.org/entity/Q53124033

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

Aflibercept and Docetaxel vers ...... d, controlled phase III trial.

@en

Aflibercept and Docetaxel vers ...... d, controlled phase III trial.

@nl

type

label

Aflibercept and Docetaxel vers ...... d, controlled phase III trial.

@en

Aflibercept and Docetaxel vers ...... d, controlled phase III trial.

@nl

prefLabel

Aflibercept and Docetaxel vers ...... d, controlled phase III trial.

@en

Aflibercept and Docetaxel vers ...... d, controlled phase III trial.

@nl

P1433

Q53124033-1728BFD8-B600-4769-9DB5-4D7CC6BCEF5B

P1476

Q53124033-79A92599-A44B-4E9B-A2F4-E38C88CF1F34

P2093

Q53124033-05246759-933A-4049-B850-EE9AB575CE58

Q53124033-2633246F-33E8-4513-879E-AB330B8C36CF

Q53124033-2E236CA2-340D-40D5-B1E3-0C87F373C51E

Q53124033-3AD99DC4-9FAD-40E8-84DF-8E2B9B90121A

Q53124033-5C7830D2-24D6-493D-8AF7-1EA00DAD5130

Q53124033-6293BAD8-3C6F-49DD-A22E-9F3DAA876124

Q53124033-84BAEAFC-D122-4BF2-9E7A-2991A75186F5

Q53124033-8CD469E2-A81C-4801-935E-3615632647DE

Q53124033-9844A2BC-8E7B-4043-8F82-1C774D548957

Q53124033-A562D89E-F4CA-4CF7-94CC-9B0274A23816

P304

Q53124033-1BA3FC0B-AF54-4CFC-9A18-F6B9BFBF0873

P31

Q53124033-99B6C90B-F6C8-4C9A-8CA9-DE9B8CBAAC57

P356

Q53124033-C535C79D-5AF1-443C-B05C-57C508F6FA8E

P407

Q53124033-B375DC47-01E3-42B8-BB72-DCFF2ABFFC29

P433

Q53124033-812B1ABA-1A59-460E-A1C1-C7A9F421F517

P478

Q53124033-3023666D-66C6-49FE-9C4E-A7BFC2A4D430

P50

Q53124033-56B7E89E-3044-4A36-9B50-B1400E7B8D9C

P577

Q53124033-8B4829D7-072E-4396-B8B9-6D37A4C50DBB

P698

Q53124033-5659AEF3-6EC8-41C0-A8EE-4CD5810A67A9

P921

Q53124033-48900592-8BA7-41DC-B6EF-D7F2C960AD25

Q53124033-7BC0A1C1-D6ED-4AB3-B367-1A7B15CD3FA3

P356

JCO.2012.42.6932

P1433

Journal of Clinical Oncology

P1476

Aflibercept and Docetaxel vers ...... d, controlled phase III trial.

@en

P2093

Augustin Rey

http://www.w3.org/2001/XMLSchema#string

Clarissa Baldotto

http://www.w3.org/2001/XMLSchema#string

Frances A Shepherd

http://www.w3.org/2001/XMLSchema#string

Giorgio Scagliotti

http://www.w3.org/2001/XMLSchema#string

Jaafar Bennouna

http://www.w3.org/2001/XMLSchema#string

Mustafa Ozguroglu

http://www.w3.org/2001/XMLSchema#string

Nicholas Thatcher

http://www.w3.org/2001/XMLSchema#string

Silvia Novello

http://www.w3.org/2001/XMLSchema#string

Solenn Le-Guennec

http://www.w3.org/2001/XMLSchema#string

Tudor Eliade Ciuleanu

http://www.w3.org/2001/XMLSchema#string

P304

3640-3647

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2012.42.6932

http://www.w3.org/2001/XMLSchema#string

P407

P433

29

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-09-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22965962

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial